

[REDACTED]

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

REGENERON PHARMACEUTICALS, INC.,  
Petitioner,

v.

NOVARTIS PHARMA AG,  
NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,  
Patent Owner.

---

Case No. IPR2021-00816  
U.S. Patent No. 9,220,631

---

**DECLARATION OF W. GREG SAWYER, PH.D.**

**TABLE OF CONTENTS**

I. INTRODUCTION .....1

II. SUMMARY OF OPINIONS .....1

    A. Written Description (112) .....1

    B. Inventorship (102f).....2

    C. Enablement (112) .....3

III. QUALIFICATIONS .....4

IV. BACKGROUND OF THE TECHNOLOGY .....8

V. PERSON OF ORDINARY SKILL IN THE ART (POSITA) .....11

VI. UNDERSTANDING THE LAW .....14

    A. New Matter / Written Description (35 U.S.C. § 112).....14

    B. Inventorship (35 U.S.C. § 102(f)) .....15

    C. Enablement (35 U.S.C. § 112) .....16

VII. CLAIM CONSTRUCTION .....17

VIII. WRITTEN DESCRIPTION .....20

    A. The Specification Does Not Demonstrate Possession of a Syringe  
    Having 1 µg to 25 µg of Silicone Oil and a Break Loose Force Less  
    Than 11N for up to 12 Months.....20

        1. The '352 Application (Ex. 2227) .....22

        2. EP '649 (Ex. 2014).....30

    B. The Specification Does Not Demonstrate Possession of a 1 ml Syringe  
    Having 1 µg to 25 µg or 3 µg to 25 µg of Silicone Oil and a Break  
    Loose Force of Less Than 11N .....32

IX. INVENTORSHIP .....36

    A. The Claimed Invention in the Substitute Claims .....36

    B. Vetter Employees Made Significant Contributions to the Claimed  
    Invention in the '631 Patent .....41

        1. The Novartis Inventors Did Not Have a Definite and Permanent  
        Idea Before Working with Vetter .....41

        2. Vetter's Work to Conceive of the Silicone Oil Ranges.....49



3. Additional Documents Confirming Vetter’s Contribution to Conception .....70

X. ENABLEMENT .....73

A. The ’352 Application Fails to Teach a POSITA How to Make a Pre-filled Syringe Where the Syringe Barrel Comprises “About 1 µg” or “About 3 µg” of Silicone Oil .....74

B. The Prior Art Does Not Disclose How to Make a Pre-filled Syringe Where the Syringe Barrel Comprises “About 1 µg” or “About 3 µg” of Silicone Oil .....81

1. Boulange (WO 2009/030976) (Ex. 1008).....81

2. [REDACTED] .....83

3. Fries (Ex. 1012).....84

4. Hioki (US 2011/0276005) (Ex. 1020) .....85

5. Chan (Ex. 2022) .....86

C. Undue Experimentation Would be Necessary to Achieve the Minimum Claimed Amounts of Silicone Oil While Also Maintaining the Claimed Break Loose and Slide Force Amounts .....87

XI. DECLARATION .....90

**TABLE OF REFERENCED DOCUMENTS**

Ex. 1001	U.S. Patent No. 9,220,631 (“the ’631 Patent”)
Ex. 1002	Prosecution File History of U.S. Patent No. 9,220,631
Ex. 1007	PCT Patent Publication No. WO 2011/006877 to Sigg <i>et al.</i> (“Sigg”)
Ex. 1008	PCT Patent Publication No. WO 2009/030976 to Boulange <i>et al.</i> (“Boulange”)
Ex. 1011	Bhavnes D. Shah & Bhupendra G. Prajapati, <i>Pre-Filled Syringes: A New Concept</i> , PHARMA BIO WORLD 51 (2009) (“Shah”)
Ex. 1012	Arno Fries, <i>Drug Delivery of Sensitive Biopharmaceuticals With Prefilled Syringes</i> , 9(5) DRUG DELIVERY TECH. 22 (2009) (“Fries”)
Ex. 1015	Sandeep Nema & John D. Ludwig, <i>Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging</i> (3rd ed. 2010) (“Nema Vol. 1”)
Ex. 1016	Sandeep Nema & John D. Ludwig, <i>Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing</i> (3rd ed. 2010) (“Nema Vol. 2”)
Ex. 1019	U.S. Pharmacopeia, <i>USP 789, Particulate Matter in Ophthalmic Solutions, USP 34 NF 29</i> (2011)
Ex. 1020	U.S. Patent Publication No. 2011/276005 to Hioki <i>et al.</i> (“Hioki”)
Ex. 1021	PCT Patent Publication No. WO 2007/149334 to Furfine <i>et al.</i> (“Furfine”)
Ex. 1028	International Organization for Standardization, <i>ISO 11040-4 Prefilled Syringes – Part 4: Glass Barrels for Injectables</i> (2nd ed. 2007) (“ISO 11040-4”)
Ex. 1029	PCT Patent Publication No. WO 2008/077155 to Lam <i>et al.</i> (“Lam”)
Ex. 1043	International Standard ISO-9626, <i>Stainless steel needle tubing for the manufacture of medical devices – Amendment 1</i> , ISO 9626:1991/Amd.1:2001(E) (“ISO-9626”)



Ex. 1044	Advait Badkar, <i>et al. Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches</i> , American Association of Pharmaceutical Sciences, June 2011, 12(2): 564-572 (“Badkar”)
Ex. 1082	U.S. Pharmacopeia, <i>USP 789, Particulate Matter in Ophthalmic Solutions, USP 32 NF 27</i> (2009)
Ex. 1109	Deposition of Kim Cameron, Ph.D., IPR2021-00816 (3/17/2022) – Filed Under Seal
Ex. 1110	Persson, et. al., <i>Elastic contact mechanics: Percolation of the contact area and fluid squeeze-out</i> , Eur. Phys. J. E. (2012)
Ex. 1112	NOVITC(CH)00137958 – Novartis Confidential Internal Memorandum Filed Under Seal
Ex. 1113	NOVITC(CH)00143346 – Novartis Confidential Internal Memorandum Filed Under Seal
Ex. 1114	NOVITC(CH)00258369 – Novartis Confidential Internal Memorandum Filed Under Seal
Ex. 1115	“Highlights of Prescribing Information,” Lucentis, FDA, June 2006, available at <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf</a>
Ex. 1116	NOVITC(CH)00195649 – Vetter Confidential Memorandum Filed Under Seal
Ex. 1117	NOVITC(CH)00145642 – Novartis Confidential Meeting Minutes Filed Under Seal
Ex. 1118	NOVITC(CH)00144912 – Novartis Confidential Meeting Minutes Filed Under Seal
Ex. 1119	NOVITC(CH)00205699 – Vetter Confidential Presentation Filed Under Seal
Ex. 1120	NOVITC(CH)00184035 – Vetter Confidential Memorandum Filed Under Seal
Ex. 1121	NOVITC(CH)00198709 – Vetter Confidential Presentation Filed Under Seal

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.